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Reply to “Susceptibility of Streptococcus pyogenes to Trimethoprim-
Sulfamethoxazole”
Asha C. Bowen,a Steven Y. C. Tong,a Jonathan R. Carapetisb
Menzies School of Health Research, Darwin, Northern Territory, Australiaa; Telethon Institute for Child Health Research, Perth, Western Australia, Australiab
We thank Gelfand et al. (1) for their interest in our article onthe in vitro susceptibility of Streptococcus pyogenes to trim-
ethoprim-sulfamethoxazole (SXT) (2). We agree that the two
cases outlined by Gelfand et al. act as cautionary points for clinical
practice, as there are currently no good clinical trial data to sup-
port the use of SXT for the treatment of S. pyogenes skin and soft
tissue infections (SSTI). Our aim in publishing the in vitro data is
to challenge the misconception that all S. pyogenes isolates are
inherently resistant to SXT and hence open the way for clinical
trials to more precisely determine the role for SXT in the treat-
ment of S. pyogenes infections.
In the two clinical scenarios presented by Gelfand et al., the
absence of SXT susceptibility data for the S. pyogenes isolates is
concerning. Other reasons for treatment failure that are not elu-
cidated include incomplete adherence, poor absorption, and the
reality that the conditions of both of these patients might have
deteriorated regardless of the antibacterial used. One wonders
why the authors prescribed SXT for these SSTI despite their un-
derstanding of the traditional teaching that S. pyogenes is largely
resistant to SXT. Perhaps it was due to the need for a simple,
palatable, oral antibacterial regimen that would treat undifferen-
tiated SSTI, in the era of highly methicillin-resistant Staphylococ-
cus aureus (MRSA) prevalence.We are in agreement with Gelfand
et al. that human clinical studies are urgently needed to respond to
this challenge.
The results of our clinical trial comparing oral SXT with intra-
muscular benzathine penicillin for impetigo treatment will in-
form treatment decisions and generate confidence in the use of
SXT for impetigo treatment in our region and possibly beyond. To
date, with recruitment of 660 participants completed, despite two-
thirds of the participants presenting with severe impetigo, none
have been hospitalized with invasive S. pyogenes infection due to
presumed treatment failure. Although the numbers in our study
are not large enough to detect a trend for bacteremia or other
complications of inadequate treatment, we might have seen clin-
ical outcomes similar to those Gelfand et al. have experienced if
SXT really has no role in the treatment of impetigo. Spontaneous
resolution of mild impetigo may occur; however, the natural his-
tory of impetigo, particularly when severe, is neither completely
understood nor benign (3).
We agree that the role of thymidine and its availability in the
context of damaged host tissues (4) are unknown with respect
to the treatment of SSTI with SXT. There are now numerous trials
under way that involve the use of SXT for SSTI (http:
//clinicaltrials.gov/), and the results are eagerly awaited to better
define the clinical utility of SXT in such settings.
Rather than claiming in vitro data being less relevant than clin-
ical efficacy, we would argue that in vitro data should be used to
inform the design of appropriate clinical trials to determine the
clinical role for SXT, particularly in an era with a truncated anti-
microbial pipeline and high rates ofmixed SSTI due toMRSA and
S. pyogenes.
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